Partnership opportunities to find tomorrow’s treatments together
OPM is a technology based clinical stage biopharmaceutical company.
Our technologies generate multiple opportunities for complementary partners. We partner with pharmaceutical companies, AI based companies, patient associations, academic experts and companies with complementary technologies to provide value to patients. Our prime focus is oncology, although our unique kinase inhibitor platform generates innovation in multiple disease indications. Acting collectively to bring tangible benefits to patients is our “leitmotif”.
Our ongoing partnerships
Homing – helping to develop your molecule
As of 2024, OPM will be implementing an acceleration programme for your high-potential molecules. This programme allows the research project holder to transform its high-potential active compound into a promising therapeutic solution in oncology or immuno-oncology through a win-win risk sharing alliance.
Mobilising our extensive experience in the selection of effective drug candidates in oncology, OPM will select anti-cancer compounds meeting our efficacy criteria by carrying out a preclinical PoC as part of an acceleration programme. If this stage is successful, the compound will be able to continue its development until phase IIa, thanks to funding in exchange for an exclusive license for the development company.